Why Incyte (INCY) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte Corporation (INCY) Q2 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Participants Brian Corey Abrahams - RBC Capital Markets, Research Division Conor Thomas MacKay - BMO Capital Markets Equity Research David Neil Lebowitz - Citigroup Inc., Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Marc Alan Frahm - TD Cowen, Research Division Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division Salim Qader Syed - Mizuho Securities USA LLC, Research Division Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Srikripa Devarakonda - Truist Securities, Inc., Research Division Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Yuxi Dong - Jefferies LLC, Research Division Operator Greetings, and welcome to the Incyte Second Quarter 2025 Earnings Conference Call and Webcast.
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Incyte (INCY) Surpasses Q2 Earnings and Revenue Estimates
Incyte (INCY) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.39 per share. This compares to a loss of $1.82 per share a year ago.
Incyte lifts annual sales forecast for blood cancer drug after solid quarter
Incyte Corp on Tuesday raised its annual sales forecast for blood cancer treatment Jakafi after robust demand helped the company surpass Wall Street estimates for second-quarter revenue and profit.
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY or TECH: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Incyte (INCY) or Techne (TECH). But which of these two stocks is more attractive to value investors?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Incyte: New CEO Brings A New Possible Outcome
Incyte's new CEO, Bill Meury, signals a potential strategic pivot toward M&A, leveraging his biopharma acquisition experience. Jakafi and Opzelura remain the company's primary revenue drivers, with Jakafi delivering $709M in Q1 2025 and strong growth across indications. Q1 2025 revenue grew 20% year-over-year to $1.05B, prompting management to raise full-year guidance, reflecting confidence in core products.
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
FDA Extends INCY's Application for Opzelura Label Expansion
FDA extends review of Incyte's ruxolitinib cream for children with atopic dermatitis, delaying decision to September 2025.
